10533 results for 'motor bind latch'

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi

Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab

Quick Facts About PamrevlumabWhat is Pamrevlumab?Pamrevlumab (FG-3019) is a monoclonal antibody designed to target and inhibit the connective tissue growth factor (CTGF), a key driver of

Immunology · ImmunophenotypingCD Markers on B Cells: Development, Subsets and ImmunophenotypingB cells change their surface marker profile at every stage from bone marrow progenitor to antibody-secret

Antibiotic resistance is a growing problem in the world today. Antibiotics are becoming less and less effective as bacteria evolve to resist them. This poses a serious threat to human healt

Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa

What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c

Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne

Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About UlocuplumabWhat is Ulocuplumab?Ulocuplumab is an investigational monoclonal antibody targeting CXCR4, a chemokine receptor involved in tumor progression and immune cell

Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe

Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app

Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate

A New Era in Oncology Chimeric Antigen Receptor (CAR)-T cell therapy represents a paradigm shift in the fight against cancer, offering a personalized and powerful immunotherapy that trains a patient

Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory resp

For decades, cancer drug development has focused on blocking proteins—inhibiting enzymes, antagonizing receptors, disrupting signaling pathways. Yet this approach leaves a vast landscape of disease-d

Fenofibrate, also known as FEN, is a drug that is used to lower cholesterol levels. It works by blocking the absorption of dietary cholesterol in the small intestine and therefore, red

Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa